Fig. 1From: Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 ratEffect of empagliflozin treatment on systolic blood pressure in the lean control and the ZSF1 groups. Values are shown as mean ± SEM of n = 9–10 per group. *P < 0.05 vs control group and #P < 0.05 vs ZSF1 groupBack to article page